Entrar/Registro  
HOME SPANISH
 
Revista de Hematología
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Revista de Hematología >Year 2018, Issue 4


Chargoy-Vivaldo E, Martínez-Hernández C, Cacique-Sánchez C, Jimaréz- Rodríguez JM, Gómez-Cárdenas L
Translocations in acute lymphoblastic leukemia and five year-survival in children
Rev Hematol Mex 2018; 19 (4)

Language: Español
References: 29
Page: 165-173
PDF: 337.66 Kb.


Full text




ABSTRACT

Background: Five-year disease-free survival in acute lymphoblastic leukemia (ALL) is greater than 80% in developed countries; in Oaxaca a lower survival is observed. It is important to know the epidemiology of translocations associated with poor prognosis and the results of the treatments used.
Objective: To determine the 5-year survival of pediatric patients diagnosed with acute lymphoblastic leukemia according to the treatment prescribed in two hospitals of Oaxaca, Mexico.
Material and Method: A descriptive, observational, analytical and retrospective study was done. All clinical files of patients diagnosed with acute lymphoblastic leukemia in the Hospital Presidente Juárez, ISSSTE, and in the Hospital de la Niñez Oaxaqueña Dr. Guillermo Zarate Mijangos, Oaxaca, from January 2010 to December 2015 were analyzed.
Results: Survival at 5 years with Total XV and with the national protocol was 66.6% and 64.2%, respectively. The translocations found were 9:22, 1:19, 12:21, 8:21 and 6:11.
Conclusions: The most frequent translocations in Oaxaca patients were: t(9:22) and t(1:19); however, they do not impact on global survival. Pediatric population in Oaxaca has more leukemias with a poor prognosis.


Key words: Acute lymphoblastic leukemia, Disease free survival, translocations, Pediatric patients.


REFERENCIAS

  1. Jaime P, et al. Hematología, la sangre y sus enfermedades. 2ª ed. México: McGraw-Hill Interamericana, 2009;291.

  2. Inaba H, et al. Acute lymphoblastic leukaemia. Lancet 2013;381(9881):1943-1955.

  3. Layton-Tovar. Factores de pronóstico en leucemia linfoblástica aguda pediátrica: posibles marcadores moleculares. Rev Med Inv 2015;3(1):85-91.

  4. Ortega SM, et al. Leucemia linfoblástica aguda. Med Int Mex 2007;23(1):26-33.

  5. Douer DM. Novel treatment in acute lymphocytic leukemia. Adv Hematol 2014;12(4):19-22.

  6. Hunger SP, et al. Acute lymphoblastic leukemia in children. N Engl J Med 2015;373(16):1541-52.

  7. Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23(4):655-74.

  8. Instituto Nacional de Estadística y Geografía. Estadística a propósito del día mundial contra el cáncer. Aguascalientes, México; 2016.

  9. Guía de Evidencias y Recomendaciones: Guía de Práctica Clínica Diagnóstico oportuno de la Leucemia Aguda en pediatría en primer y segundo nivel de atención. México, CENETEC; 2017

  10. Chiaretti S, et al. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 2014; 6(1):e2014073.

  11. Cuccaro A, et al. Prognostic factors in Hodgkin lymphoma. Mediterr J Hematol Infect Dis 2014;6(1):1-14.

  12. Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson Tratado de pediatría. 18ª ed. Barcelona: Elsevier, 2008.

  13. Secretaría de Salud. Protocolo de la atención para leucemia linfoblástica. Guía clínica y Esquema de Tratamiento. México: INSP, 2012:1-31.

  14. Verduzco-Rodríguez L, Verduzco-Aguirre HC, López-Ariza B. Leucemia linfoblástica aguda hiperdiploide en niños. Rev Hematol Mex 2012;13(4):172-76.

  15. Advani AS, et al. Highlights in acute lymphoblastic leukemia from the 2013 American Society of Hematology Annual Meeting and Exposition. Adv Hematol 2014;12(6):7-12.

  16. Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasm and acute leukemia. Blood 2016;127(20):2391-05.

  17. Cotran R, et al. Patología estructural y funcional. 8ª ed. España: Elsevier; 2010.

  18. Villasís Keever MA. JAGENBR. Metaanálisis sobre los factores pronóstico relacionados con la mortalidad en niños con leucemia linfoblástica aguda. Bol Méd Hosp Infant Méx 2012;69:175-188.

  19. Pui CH, et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there. Blood 2012;120(6):1165-1174.

  20. Winter SS. Pediatric acute leukemia therapies informed by molecular analysis of high-risk disease. Hematology Am Soc Hematol Educ Program 2011;2011:366-373.

  21. Rives S y col. Leucemia linfoblástica aguda T pediátrica: Análisis de supervivencia y factores pronósticos en 4 protocolos consecutivos del grupo cooperativo multicéntrico SHOP. Med Clin 2012;139(4):141-149.

  22. Cooper SL, et al. Treatment of pediatric acute lymphoblastic leukemia. Pediatric Clin North Am 2015;62(1):61-73.

  23. Diller L. Adult primary care after childhood acute lymphoblastic leukemia. N Engl J Med 2011;365:1417-24.

  24. Passaro D, et al. CXCR4 Is required for leukemia - initiating cell activity in T cell acute lymphoblastic leukemia. Cancer Cell 2015;27(6):769-779.

  25. Vargas-Vallejo M y col. Alteraciones citogenéticas en niños con leucemia aguda linfoblástica en Tabasco. Salud en Tabasco 2011;17(1):22-29.

  26. Atienza AL. Leucemia linfoblástica aguda. Pediatr Integral 2012;16(6):453-462.

  27. García BM y col. Leucemia en la infancia, signos de alerta. An Pediatr Contin 2012;10(1):1-7.

  28. Mullighan C. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2012;1:389-396.

  29. Calderón-Pizaña D y col. Identificación de marcadores cromosómicos en pacientes con leucemia linfoblástica aguda. Rev Hosp Jua Mex 2012;79(4):243-251.






>Journals >Revista de Hematología >Year 2018, Issue 4
 

· Journal Index 
· Links 






       
Copyright 2019